Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jaguar Health's enterprise value is $15.91 Mil.
Jaguar Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-32.52 Mil. Therefore, Jaguar Health's EV-to-EBITDA for today is -0.49.
The historical rank and industry rank for Jaguar Health's EV-to-EBITDA or its related term are showing as below:
JAGX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.24 Med: -0.96 Max: -0.41
Current: -0.49
During the past 13 years, the highest EV-to-EBITDA of Jaguar Health was -0.41. The lowest was -2.24. And the median was -0.96.
JAGX's EV-to-EBITDA is ranked worse than 100% of 400
companies
in the Biotechnology industry
Industry Median: 13.725
vs JAGX: -0.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jaguar Health's PE Ratio (TTM) for today is calculated as:
Jaguar Health's share price for today is $0.5968.
Jaguar Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-827.901.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Jaguar Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jaguar Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jaguar Health's EV-to-EBITDA falls into.
Jaguar Health's current Enterprise Value is $15.91 Mil.
Jaguar Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a EV-to-EBITDA of -0.49 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jaguar Health. According to the industry distribution chart, Jaguar Health ranks #999999 out of 400 companies in the Biotechnology industry.
Is Jaguar Health's EV-to-EBITDA too high?
Jaguar Health's current EV-to-EBITDA is -0.49. Based on the distribution chart, Jaguar Health ranks #999999 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jaguar Health has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's EV-to-EBITDA compare to APVO and GRI?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #999999 out of 400 companies for EV-to-EBITDA. This places Jaguar Health in the lower half of its industry. The industry median EV-to-EBITDA is 13.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.73, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jaguar Health. For the Biotechnology industry, the median EV-to-EBITDA is 13.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current EV-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Based on GuruFocus' analysis, Jaguar Health (JAGX) is currently considered Possible Value Trap. The stock's GF Value™ is $111.73, compared to a current price of $0.60 — trading 99.5% below its estimated fair value. The current EV-to-EBITDA is -0.49. Jaguar Health's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jaguar Health (JAGX), the current EV-to-EBITDA is -0.49 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jaguar Health (JAGX) Overvalued in 2026?
Based on GuruFocus' analysis, Jaguar Health stock appears to be undervalued.
The current stock price of $0.60 is trading 99.5% below its estimated GF Value™ of $111.73.
GuruFocus considers Jaguar Health to be Possible Value Trap.
Key valuation signals for JAGX:
EV-to-EBITDA: -0.49
GF Value™: $111.73 vs. price of $0.60 (99.5% below fair value)
No single metric tells the full story. See the JAGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
38GF Score
Get the complete analysis for JAGX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
